Get the Stockscreener App
203.34
0.38%
0.4112
Natera Inc stock is traded at $203.34, with a volume of 19,920.
It is up +0.38% in the last 24 hours and up +11.97% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$203.75
Open:
$202.6
24h Volume:
19,920
Relative Volume:
0.02
Market Cap:
$28.95B
Revenue:
$2.31B
Net Income/Loss:
$-208.16M
P/E Ratio:
-132.33
EPS:
-1.5366
Net Cash Flow:
$76.11M
1W Performance:
-1.55%
1M Performance:
+11.97%
6M Performance:
+6.40%
1Y Performance:
+32.99%
1-Day Range:
$202.60
$204.99
1-Week Range:
$192.79
$212.77
52-Week Range:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
202.75 | 29.09B | 2.31B | -208.16M | 76.11M | -1.5366 |
TMO
Thermo Fisher Scientific Inc
|
468.89 | 174.55B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.80 | 125.45B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.18 | 44.95B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
116.45 | 32.65B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
309.77 | 30.42B | 3.17B | 642.63M | 516.49M | 10.77 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera's Signatera data suggests select breast cancer patients could skip surgery - MSN
Natera awarded 30% ongoing royalty in MRD patent litigation - MSN
M&T Bank Corp Increases Stock Position in Natera, Inc. $NTRA - MarketBeat
What Natera (NTRA)'s New Prospera Transplant Data Momentum Means For Shareholders - simplywall.st
Is It Too Late To Consider Natera (NTRA) After Its Strong Multi Year Share Price Run? - Yahoo Finance
Teacher Retirement System of Texas Has $15.06 Million Holdings in Natera, Inc. $NTRA - MarketBeat
Natera Urges High Court To Reject CareDx's False Ad Petition - Law360
Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Natera, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm - TMX Newsfile
Universal Beteiligungs und Servicegesellschaft mbH Has $30.18 Million Stake in Natera, Inc. $NTRA - MarketBeat
Natera, Inc. ($NTRA) CEO and President 2025 Pay Revealed - Quiver Quantitative
[ARS] Natera, Inc. SEC Filing - Stock Titan
Natera (NASDAQ: NTRA) details 2026 meeting agenda, pay votes and equity plan expansion - Stock Titan
Unveiling Natera (NTRA) Q4 outlook: Wall Street estimates for key metrics - MSN
Is It Too Late To Consider Natera (NTRA) After Its Recent Share Price Surge? - simplywall.st
Why (NTRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Natera (NTRA) Showcases Promising Evidence for Prospera Test at ISHLT Meeting - GuruFocus
17 transplant studies show Prospera flags earlier heart, lung warning signs - Stock Titan
Natera co-founder Sheena Jonathan sells $299,440 in shares By Investing.com - Investing.com India
Natera co-founder Sheena Jonathan sells $299,440 in shares - Investing.com
Natera (NTRA) co-founder’s family trusts sell 1,500 shares under 10b5-1 plan - Stock Titan
Judge hands Natera 30% ongoing royalty in MRD patent battle - MSN
Natera positioned to capture growing $20 billion MRD opportunity: analyst - MSN
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA) - Yahoo Finance
3 Reasons We’re Fans of Natera (NTRA) - Yahoo Finance
Natera, Inc. $NTRA Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Natera, Inc. (NTRA) Stock Analysis: A 23.78% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Natera Sees RS Rating Improve To 76 - Investor's Business Daily
Court orders 30% ongoing royalty for Natera in patent dispute - MSN
KBC Group NV Buys 14,346 Shares of Natera, Inc. $NTRA - MarketBeat
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know - Yahoo Finance
Cwm LLC Has $19 Million Holdings in Natera, Inc. $NTRA - MarketBeat
Natera, UFP Technologies, Mettler-Toledo, and Viatris shares are soaring, what you need to know - MSN
Chicago Capital LLC Purchases 12,805 Shares of Natera, Inc. $NTRA - MarketBeat
Natera, Inc. (NASDAQ:NTRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Natera (NASDAQ:NTRA) Rating Increased to Buy at Wall Street Zen - MarketBeat
Class Action Certification and CLARITY MRD Data Might Change The Case For Investing In Natera (NTRA) - simplywall.st
NTRA Technical Analysis | Trend, Signals & Chart Patterns | NATERA INC (NASDAQ:NTRA) - ChartMill
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera (NTRA) Tops Q4 Earnings and Revenue Estimates - Eastern Progress
Is It Time To Reassess Natera (NTRA) After Its Mixed Share Price Performance? - simplywall.st
Barclays Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $280 - Moomoo
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
Natera, Inc. (NASDAQ:NTRA) Short Interest Up 47.2% in March - MarketBeat
NTRA Initiated Coverage On by William Blair -- Rating Outperform - GuruFocus
NATERA INC : WILLIAM BLAIR INITIATES COVERAGE WITH OUTPERFORM RATING - Moomoo
Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst - Benzinga
Natera Inc stock (US6323071042): Is cell-free DNA testing strong enough to unlock sustained growth? - AD HOC NEWS
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - BioSpace
William Blair initiates Natera stock with Outperform on growth outlook - Investing.com
William Blair initiates Natera stock with Outperform on growth outlook By Investing.com - Investing.com India
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Natera Inc Stock (NTRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Apr 06 '26 |
Option Exercise |
9.59 |
58,292 |
559,020 |
2,410,772 |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
Apr 01 '26 |
Sale |
203.31 |
8,400 |
1,707,814 |
224,885 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Apr 01 '26 |
Sale |
202.30 |
3,000 |
606,899 |
147,882 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Mar 31 '26 |
Option Exercise |
9.59 |
41,708 |
399,980 |
2,352,480 |
1.96%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):